Last updated: 2026-09-04 21:53:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Onconetix, Inc. (ONCO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1,02, with a market capitalization of $2,95M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,59 to $209,50. This page covers its latest market performance, valuation, price trends and company information.
$2,95M | |
$0,74 | |
$90 950,00 | |
$0,59 | |
$0,74 | |
3,22M | |
-- | |
-- | |
$209,50 | |
$0,59 | |
-- | |
-- |
Onconetix, Inc. (ONCO) is trading at $0,89 in after-hours trading as of 2026-09-04 21:51:00, up 19,89% ($0,15) from the regular-session close of $0,74.
After-hours trading shows how investors are pricing ONCO after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Onconetix, Inc. (ONCO) moved from $0,60 to $1,02, representing a gain of 70,17% ($0,42).
The stock traded between $0,70 and $1,04 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 1,03 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0,2%
ONCO is currently trading at $1,02, placing it 0,2% of the way from its 52-week low of $0,59 to its 52-week high of $209,50. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 2 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Onconetix, Inc. (ONCO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.